Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
United Therapeutics Corporation has 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 7 distinct examiners and 6 distinct art units. This distribution shows that the company's prosecution efforts are spread across a wide range of examiners and technical units. The involvement of 6 distinct art units suggests that the company's pharmaceutical developments are being reviewed by several different specialized groups within the patent office.
WARD, PAUL V is the busiest examiner for the portfolio, currently managing 1 pending office action. This examiner is one of the 7 distinct examiners involved in the company's 7 pending office actions. Because each examiner is handling exactly one matter, the workload is perfectly distributed across the examiners. This structure indicates that no single examiner has a dominant influence over the company's current pending portfolio, requiring a broad approach to prosecution management.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18586056 | TREATMENT FOR INTERSTITIAL LUNG DISEASE | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 13d |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | — |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | — |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | — |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 13d |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | — |
| 18106782 | TREPROSTINIL ILOPROST COMBINATION THERAPY | ARMSTRONG, SUSANNAH SIPPLE | — |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | — |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | — |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1622 | 1 |
| 1628 | 1 |
| 1616 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18586056 | TREATMENT FOR INTERSTITIAL LUNG DISEASE | WARD, PAUL V | 1622 | DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18416389 | TREPROSTINIL ANALOGS AND RELATED METHODS OF MAKING AND USING | MOU, LIYUAN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18106782 | TREPROSTINIL ILOPROST COMBINATION THERAPY | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103DP | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18147929 | ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL | SCHUBERG, LAURA J | 1631 | §102§103§112DP | Non-Final OA | — | Pending | Dec 29, 2022 |
| 17894709 | METHOD TO OBTAIN CELLS FROM LUNG TISSUE | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17164693 | EXTRACELLULAR VESICLES WITH ENHANCED POTENCY | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 13d | Pending | Feb 01, 2021 |
| 17003431 | METHODS AND COMPOSITIONS FOR CULTURING ALVEOLAR CELLS | GONZALES, JOSEPHINE MARIA | 1638 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUnited Therapeutics Corporation has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Paul V Ward has the most, with 1 of United Therapeutics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
